Reassessing the contraindication of zolmitriptan and serotonin reuptake inhibitors: an evidence-based pharmacotherapeutic case report.
Boutilier
A S W
AS
College of Pharmacy, Dalhousie University, Halifax, Nova Scotia, Canada.
Gardner
D M
DM
D000075202:Contraindications; D003863:Depression / Q000188:drug therapy; D004347:Drug Interactions; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy; D023303:Oxazolidinones / Q000009:adverse effects / Q000627:therapeutic use; D017374:Paroxetine / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D017366:Serotonin Receptor Agonists / Q000009:adverse effects / Q000627:therapeutic use; D020230:Serotonin Syndrome / Q000139:chemically induced; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D014363:Tryptamines
D023303:Oxazolidinones; D017374:Paroxetine; D017366:Serotonin Receptor Agonists; D017367:Selective Serotonin Reuptake Inhibitors; D014363:Tryptamines; C089750:zolmitriptan